These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15122081)

  • 1. Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
    de Jonge MJ; Droz JP; Paz-Ares L; van Oosterom AT; de Wit R; Chollet P; Baron B; Lacombe D; Mettinger K; Fumoleau P;
    Invest New Drugs; 2004 Aug; 22(3):329-33. PubMed ID: 15122081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.
    Baka S; Ranson M; Lorigan P; Danson S; Linton K; Hoogendam I; Mettinger K; Thatcher N
    Eur J Cancer; 2005 Jul; 41(11):1547-50. PubMed ID: 16026691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.
    Punt CJ; de Jonge MJ; Monfardini S; Daugaard G; Fiedler W; Baron B; Lacombe D; Fumoleau P;
    Eur J Cancer; 2004 Jun; 40(9):1332-4. PubMed ID: 15177492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
    Raymond E; Campone M; Stupp R; Menten J; Chollet P; Lesimple T; Fety-Deporte R; Lacombe D; Paoletti X; Fumoleau P; ; ;
    Eur J Cancer; 2002 Jul; 38(10):1348-50. PubMed ID: 12091065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
    Quinn DI; Tsao-Wei DD; Twardowski P; Aparicio AM; Frankel P; Chatta G; Wright JJ; Groshen SG; Khoo S; Lenz HJ; Lara PN; Gandara DR; Newman E
    Invest New Drugs; 2021 Jun; 39(3):812-820. PubMed ID: 33409898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
    Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
    Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.
    Galsky MD; Hahn NM; Wong B; Lee KM; Argiriadi P; Albany C; Gimpel-Tetra K; Lowe N; Shahin M; Patel V; Tsao CK; Oh WK
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1259-65. PubMed ID: 26464352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
    Gomez-Abuin G; Winquist E; Stadler WM; Pond G; Degendorfer P; Wright J; Moore MJ
    Invest New Drugs; 2007 Apr; 25(2):181-5. PubMed ID: 16983508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
    Schöffski P; Herr A; Vermorken JB; Van den Brande J; Beijnen JH; Rosing H; Volk J; Ganser A; Adank S; Botma HJ; Wanders J
    Eur J Cancer; 2002 Apr; 38(6):807-13. PubMed ID: 11937315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
    Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
    Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
    Pitot HC; Knost JA; Mahoney MR; Kugler J; Krook JE; Hatfield AK; Sargent DJ; Goldberg RM
    Cancer; 2000 Oct; 89(8):1699-705. PubMed ID: 11042563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
    Michaelson MD; Ryan DP; Fuchs CS; Supko JG; Garcia-Carbonero R; Paul Eder J; Clark JW
    Cancer; 2003 Jan; 97(1):148-54. PubMed ID: 12491516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
    Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
    Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
    Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.